Cargando…

Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy

After neoadjuvant chemoradiotherapy (NCRT) in locally advanced esophageal squamous cell cancer (ESCC), roughly 40% of the patients may achieve pathologic complete response (pCR). Those patients may benefit from organ-saving strategy if the probability of pCR could be correctly identified before esop...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yue, Liu, Jun, Li, Hong-xuan, Cai, Xu-wei, Li, Zhi-gang, Ye, Xiao-dan, Teng, Hao-hua, Fu, Xiao-long, Yu, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933499/
https://www.ncbi.nlm.nih.gov/pubmed/33680935
http://dx.doi.org/10.3389/fonc.2020.615167
_version_ 1783660624529588224
author Li, Yue
Liu, Jun
Li, Hong-xuan
Cai, Xu-wei
Li, Zhi-gang
Ye, Xiao-dan
Teng, Hao-hua
Fu, Xiao-long
Yu, Wen
author_facet Li, Yue
Liu, Jun
Li, Hong-xuan
Cai, Xu-wei
Li, Zhi-gang
Ye, Xiao-dan
Teng, Hao-hua
Fu, Xiao-long
Yu, Wen
author_sort Li, Yue
collection PubMed
description After neoadjuvant chemoradiotherapy (NCRT) in locally advanced esophageal squamous cell cancer (ESCC), roughly 40% of the patients may achieve pathologic complete response (pCR). Those patients may benefit from organ-saving strategy if the probability of pCR could be correctly identified before esophagectomy. A reliable approach to predict pathological response allows future studies to investigate individualized treatment plans. METHOD: All eligible patients treated in our center from June 2012 to June 2019 were retrospectively collected. Radiomics features extracted from pre-/post-NCRT CT images were selected by univariate logistic and LASSO regression. A radiomics signature (RS) developed with selected features was combined with clinical variables to construct RS+clinical model with multivariate logistic regression, which was internally validated by bootstrapping. Performance and clinical usefulness of RS+clinical model were assessed by receiver operating characteristic (ROC) curves and decision curve analysis, respectively. RESULTS: Among the 121 eligible patients, 51 achieved pCR (42.1%) after NCRT. Eighteen radiomics features were selected and incorporated into RS. The RS+clinical model has improved prediction performance for pCR compared with the clinical model (corrected area under the ROC curve, 0.84 vs. 0.70). At the 60% probability threshold cutoff (i.e., the patient would opt for observation if his probability of pCR was >60%), net 13% surgeries could be avoided by RS+clinical model, equivalent to implementing organ-saving strategy in 31.37% of the 51 true-pCR cases. CONCLUSION: The model built with CT radiomics features and clinical variables shows the potential of predicting pCR after NCRT; it provides significant clinical benefit in identifying qualified patients to receive individualized organ-saving treatment plans.
format Online
Article
Text
id pubmed-7933499
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79334992021-03-06 Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy Li, Yue Liu, Jun Li, Hong-xuan Cai, Xu-wei Li, Zhi-gang Ye, Xiao-dan Teng, Hao-hua Fu, Xiao-long Yu, Wen Front Oncol Oncology After neoadjuvant chemoradiotherapy (NCRT) in locally advanced esophageal squamous cell cancer (ESCC), roughly 40% of the patients may achieve pathologic complete response (pCR). Those patients may benefit from organ-saving strategy if the probability of pCR could be correctly identified before esophagectomy. A reliable approach to predict pathological response allows future studies to investigate individualized treatment plans. METHOD: All eligible patients treated in our center from June 2012 to June 2019 were retrospectively collected. Radiomics features extracted from pre-/post-NCRT CT images were selected by univariate logistic and LASSO regression. A radiomics signature (RS) developed with selected features was combined with clinical variables to construct RS+clinical model with multivariate logistic regression, which was internally validated by bootstrapping. Performance and clinical usefulness of RS+clinical model were assessed by receiver operating characteristic (ROC) curves and decision curve analysis, respectively. RESULTS: Among the 121 eligible patients, 51 achieved pCR (42.1%) after NCRT. Eighteen radiomics features were selected and incorporated into RS. The RS+clinical model has improved prediction performance for pCR compared with the clinical model (corrected area under the ROC curve, 0.84 vs. 0.70). At the 60% probability threshold cutoff (i.e., the patient would opt for observation if his probability of pCR was >60%), net 13% surgeries could be avoided by RS+clinical model, equivalent to implementing organ-saving strategy in 31.37% of the 51 true-pCR cases. CONCLUSION: The model built with CT radiomics features and clinical variables shows the potential of predicting pCR after NCRT; it provides significant clinical benefit in identifying qualified patients to receive individualized organ-saving treatment plans. Frontiers Media S.A. 2021-02-19 /pmc/articles/PMC7933499/ /pubmed/33680935 http://dx.doi.org/10.3389/fonc.2020.615167 Text en Copyright © 2021 Li, Liu, Li, Cai, Li, Ye, Teng, Fu and Yu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yue
Liu, Jun
Li, Hong-xuan
Cai, Xu-wei
Li, Zhi-gang
Ye, Xiao-dan
Teng, Hao-hua
Fu, Xiao-long
Yu, Wen
Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
title Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
title_full Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
title_fullStr Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
title_full_unstemmed Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
title_short Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
title_sort radiomics signature facilitates organ-saving strategy in patients with esophageal squamous cell cancer receiving neoadjuvant chemoradiotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933499/
https://www.ncbi.nlm.nih.gov/pubmed/33680935
http://dx.doi.org/10.3389/fonc.2020.615167
work_keys_str_mv AT liyue radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy
AT liujun radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy
AT lihongxuan radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy
AT caixuwei radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy
AT lizhigang radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy
AT yexiaodan radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy
AT tenghaohua radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy
AT fuxiaolong radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy
AT yuwen radiomicssignaturefacilitatesorgansavingstrategyinpatientswithesophagealsquamouscellcancerreceivingneoadjuvantchemoradiotherapy